

Cancer Control Program Cancer in the Elderly Committee

200 First Street, SW Rochester, MN 55905 P: 507-266-9202 F: 507-284-1803

www.allianceforclinicaltrialsinoncology.org

Harvey J. Cohen, M.D. Hyman B. Muss, M.D. Co-Chairs

Agenda Cancer in the Elderly Committee Meeting Saturday, May 10, 2014 3:00-5:00 PM CST

Meeting available by teleconference: Dial 800-501-8979 Access Code: 1165588 Meeting available by webconference: log into www.paetec.com/conferencing, click on the "Join a Conference" option, enter 8005018979 followed by the 7-digit access code: 1165588. You will be asked to enter your name, email, phone and company. Only the name is required.

Committee Leadership		
Members:	Role	E-mail
Harvey J. Cohen, MD	Co-Chair	Harvey.cohen@duke.edu
Hyman B. Muss, MD	Co-Chair	muss@med.unc.edu
		ahurria@coh.org;
Arti Hurria, MD	Co-Vice Chair	GBradley@coh.org
Aminah Jatoi, MD	Co-Vice Chair	jatoi.aminah@mayo.edu
Jacob (Jake) Allred	Statistician	allred@mayo.edu
Karla V. Ballman, PhD	Statistician	ballman.karla@mayo.edu
Jan C. Buckner, MD	CCP Director/PI	buckner.jan@mayo.edu
Mindie Burton	CCP Administrative Assistant	burton.mindie@mayo.edu
Jo-Ellen DeLuca	Patient Advocate	joellen132@bellsouth.net
Kathy Klinger, RN, MSN, NP-		
BC, AOCN	Nurse Liaison	kklinger@hoacny.com
Jackie Lafky, MS	CCP Program Manager	Lafky.jacqueline@mayo.edu
Brandy Pitcher, MS	Statistician	brandy.pitcher@duke.edu
John Taylor, MA	Clinical Trials Manager	jtaylor1@uchicago.edu
Kimberly Thomas, MS	Protocol Coordinator	kthoma16@uchicago.edu

- I. Scientific Presentations (10 minutes presentation/5 minutes Q&A each)
 - A. Findings from the Institute of Medicine (IOM) report "Committee on Improving the Quality of Cancer Care: Addressing the Challenges of an Aging Population" (*Arti Hurria, MD*)
 - B. CARE: A Pilot Study Testing the Efficacy of a Psychotherapy for Older Cancer Patients (*Christian Nelson*, *PhD*)
 - C. Physical Activity and Functional Status in Older Cancer Patients (Jennifer Ligibel, MD)
 - D. Feasibility of geriatric assessment for older adults with acute myeloid leukemia (AML) receiving intensive chemotherapy on a cooperative group clinical trial: CALGB 361006 (Alliance) (*Heidi Klepin, MD*)
 - E. Geriatric Assessment Training Demonstration (Arti Hurria, MD)

II. Study Updates – Around the Room (45 minutes)

- A. Data Mining Updates (Arti Hurria, MD to provide 10 minute overview)
 - 1. Heidi Klepin, MD: (361004) Associations between comorbidity, chemotherapy toxicity, and clinical outcomes among older women receiving adjuvant therapy for breast cancer in CALGB 49907
 - 2. Arti Hurria, MD: (361007) Changes in Functional Status Among Older Adults who Receive Adjuvant Chemotherapy for Breast Cancer (Retrospective Analysis using 49907 data)
 - 3. Jeanne Mandelblatt: (369901) Observational cohort study: Chemotherapy decisions and outcomes in women age 65 or older with operable, newly diagnosed breast cancer

- Stu Lichtman, MD: (A171201) Ancillary Data Study of 49907: Standard Chemotherapy (CMF or AC) versus Capecitabine in Early-Stage Breast Cancer (BC) Patients Aged 65 and older: Results of CALGB/CTSU 49907
- 5. Aminah Jatoi, MD: (A171301) Exploring Associations Between Social Support and Clinical Outcomes in Elderly Patients Enrolled in CALGB 49907
- 6. Judy Hopkins, MD: (A171302) Musculoskeletal Events in Elderly Patients Receiving Adjuvant Chemotherapy for Breast Cancer
- Ajeet Gajra, MD: 49907 Correlative Association of Baseline Patient Attitudes Towards Chemotherapy Benefit and Self Health with QoL, Toxicity, Mental Health and Function in Women Treated on CALGB 49907
- 8. Myra Barginear, MD: Chemotherapy Induced Peripheral Neuropathy in CALGB 40101 and CALGB 70301/CTSU 70301: Prevalence and Severity As a Function of Age
- 9. Gretchen Kimmick, MD: Estimate of Survival and Validating Using the Online Prognosis Estimation from Eprognosis
- 10. Vicki Morrison, MD: Chemotherapy Dosing and Weight
- 11. Kathy Klinger, RN: Symptom Reporting Differences in the Elderly vs. Younger
- 12. Jeanne Mandelblatt, MD: Self-reported Cognitive Issues
- B. Previously Presented Concepts (5 minutes each)
 - 1. Joleen Hubbard, MD: Biomarkers of Frailty Among Patients with Colorectal Cancer
 - 2. John Grecula, MD: Phase I Evaluation of Minocycline As a Neuroprotector in Older Adult Patients Receiving Prophylactic Cranial Radiotherapy for Small Cell Lung Carcinoma
 - 3. Rachel Freedman, MD: (RU011301I) Adjuvant Ado-Trastuzumab Emtansine (T-DM1) for Older Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
 - 4. Aminah Jatoi, MD and Waddah Al-Refaie, MD: A Weekly Phone-based Intervention to Improve Outcomes in Elderly (>70 Years Old), Postoperative Pancreas Cancer Patients
 - 5. Lee Jones, PhD: Effects of Supervised Aerobic Training on Cardiorespiratory Fitness, Functional Capacity, and Cardiovascular Risk Profile in Elderly Breast Cancer Survivors: A Pilot Study
 - 6. Maryam Lustberg, MD: Social Influences on Oxytocin Receptor Expression in Mammary Tissue
- C. Open Studies (5 minutes total)
 - 1. Michael Jaklitsch, MD: 140801 Geriatric assessment for older patients considering thoracic surgery
 - Jennifer Woyach, MD: (A041202) A Randomized Phase III Study of Chlorambucil Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone In Untreated Older Patients With Chronic Lymphocytic Leukemia (CLL)
- D. Closed Studies (Publications Pending) Provided as an FYI only. See Study Tracker for additional details.
 - Ravi Vij, MD: (100801) Phase II Study of the Addition of Azacitidine (IND #87574, NCS#102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients with AML
 - Heidi Klepin, MD:(361006) Geriatric Assessment in CALGB 11001: Ph II Study Incorporating Sorafenib (IND 69896, NSC 724772) into the Therapy of Pts ≥ 60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia
 - Heidi Klepin, MD: (361101) Geriatric Assessment in CALGB 11002: Randomized Ph II Trial of Decitabine-based Induction Strategies for Pts
 <u>></u> 60 Years Old w/AML
 - 4. William Cance, MD: (159805) Laboratory Studies in Elderly Women with Breast Cancer: Companion to CALGB 9343
 - 5. (40502) A randomized phase III trial of weekly paclitaxel compared to weekly nanoparticle albumin bound NAB paclitaxel or ixabepilone with or without bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer
 - Maura Dickler, MD: (40503) Endocrine therapy with or without anti-VEGF therapy: A randomized, phase III trial of endocrine therapy alone or endocrine therapy plus bevacizumab (NSC 704865: IND 7921) for women with hormone receptor-positive advanced breast cancer
 - 7. Elizabeth Lamont, MD: (70802) Population-based assessment of cancer trial generalizability in the elderly
 - 8. Thomas Habermann, MD: (9793) A phase III trial of CHOP versus CHOP and chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in older patients with diffuse mixed, diffuse large cell and immunoblastic large cell histology non-Hodgkin's lymphoma
 - Grace Dy, MD: (N0821) A phase II first-line study of a combination of pemetrexed, carboplatin and bevacizumab in advanced nonsquamous NSCLC evaluating efficacy and tolerability in elderly patients (age >/=70 yrs) with good performance status (PS <2)

10. Waddah Al-Refaie, MD: (Z901101) Older Age and Enrollment Patterns to Surgical Oncology Trials

III. Meeting Handout – Notation Only

- A. Study Tracker
- B. Cancer in the Elderly Publications Provided in the Alliance NCORP Research Base Application